On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies-Reference-Cited by-同舟云学术

On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies

Published:2018-11-20 Issue:2 Volume:18 Page:166-183
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Unkel Steffen¹^ORCID,Amiri Marjan²,Benda Norbert³^ORCID,Beyersmann Jan⁴,Knoerzer Dietrich⁵,Kupas Katrin⁶,Langer Frank⁷,Leverkus Friedhelm⁸,Loos Anja⁹,Ose Claudia²,Proctor Tanja¹⁰,Schmoor Claudia¹¹,Schwenke Carsten¹²,Skipka Guido¹³,Unnebrink Kristina¹⁴,Voss Florian¹⁵,Friede Tim¹^ORCID

Affiliation:

1. Department of Medical StatisticsUniversity Medical Center Goettingen Goettingen Germany

2. Center for Clinical TrialsUniversity Hospital Essen Essen Germany

3. Biostatistics and Special Pharmacokinetics Unit, Federal Institute for Drugs and Medical Devices Bonn Germany

4. Institute of StatisticsUlm University Germany

5. Roche Pharma AG Grenzach Germany

6. Bristol‐Myers Squibb GmbH & Co. KGaA München Germany

7. Lilly Deutschland GmbH Bad Homburg Germany

8. Pfizer Deutschland GmbH Berlin Germany

9. Merck KGaA Darmstadt Germany

10. Institute of Medical Biometry and InformaticsUniversity of Heidelberg Heidelberg Germany

11. Clinical Trials Unit, Faculty of Medicine and Medical CenterUniversity of Freiburg Freiburg im Breisgau Germany

12. Schwenke Consulting: Strategies and Solutions in Statistics (SCO:SSIS) Berlin Germany

13. Institute for Quality and Efficiency in Health Care Cologne Germany

14. AbbVie Deutschland GmbH & Co. KG Ludwigshafen Germany

15. Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.1915

Reference74 articles.

1. Modelling Survival Data in Medical Research

2. Estimands and their role in clinical trials;Akacha M;Stat Biopharmaceutical Res,2015

3. Choosing Appropriate Estimands in Clinical Trials

4. Estimands in clinical trials - broadening the perspective

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis;BMC Medical Research Methodology;2024-01-03

2. An Overview of Regression Models for Adverse Events Analysis;Drug Safety;2023-11-25

3. A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels;Advances in Therapy;2023-10-19

4. Future directions of research into harms in randomised controlled trials;BMJ;2023-04-24

5. Important Considerations for Signal Detection and Evaluation;Therapeutic Innovation & Regulatory Science;2023-04-17